Since the US regulatory and litigation pathway for biosimilars was signed into law in March 2010, the FDA has approved 28 biosimilar products, including 16 drugs with indications for patients with cancer.
Matthew Gavidia
Advertisement
Articles by Matthew Gavidia
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
ctDNA Status Has Strong Prognostic Value, Outperforming pCR Status, in Early TNBC
2
FDA Grants Priority Review to Giredestrant for ER-Positive Early Breast Cancer
3
Dato-DXd Hits Key Secondary Efficacy End Points in First-Line TNBC
4
Bispecific-Based Approaches Highlight Key Multiple Myeloma Data Set to Emerge at EHA 2026
5